critique

**Falsification experiments:**
1. Cholinergic lesions in young animals to test if theta disruption precedes stellate neuron loss
2. Local α7 receptor antagonism in entorhinal cortex to determine effects on stellate neuron survival
3. Record stellate neurons in ChAT knockout mice to assess whether cholinergic loss directly affects these cells

**Revised confidence:** 0.6 (reduced from 0.8) - strongest hypothesis but still lacks direct causal evidence

## Overall Critique Summary:

**Major systemic weaknesses across hypotheses:**
1. **Lack of cell-type specificity**: Most targets affect multiple neuron types
2. **Assumption of causality**: Many hypotheses assume correlations are causal relationships
3. **Missing pathological context**: Limited consideration of how AD-specific pathology (tau, amyloid, inflammation) interacts with proposed mechanisms
4. **Therapeutic window unclear**: When in disease progression would these interventions be effective?

**Strongest surviving hypothesis:** Cholinergic modulation (Hypothesis 7) because it addresses a well-established early change in AD, though causality remains unproven.

**Weakest hypothesis:** Lactate utilization (Hypothesis 3) due to unsubstantiated metabolic assumptions.

**Key missing experiments across all hypotheses:**
1. Demonstration of cell-type specific vulnerability mechanisms
2. Temporal studies showing proposed mechanisms precede rather than follow stellate neuron loss
3. Rescue experiments in multiple AD models to test therapeutic potential